Scientists at Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have described GTPase KRAS and/or its mutant inhibitors reported to be useful for the treatment of cancer.
Gluetacs Therapeutics (Shanghai) Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a target protein binding moiety through a linker reported to be useful for the treatment of cancer, dermatological, neurological, respiratory and cardiovascular disorders, autoimmune diseases, infections and transplant rejection, among others.
Researchers at Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have identified aromatic amide derivatives acting as kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.
Scientists at Sichuan Huiyu Pharmaceutical Co. Ltd. and Sichuan Huiyu Seacross Pharma Technology Ltd. have disclosed pyridazinopyridone derivatives acting as son of sevenless homolog 1 (SOS1) inhibitors. As such, they are reported to be useful for the treatment of cancer, gingival fibromatosis, cardiofaciocutaneous and Noonan syndromes.
Pancreatic cancer is a highly lethal digestive malignancy with a 5-year survival rate of 10%. So far, the available therapeutic strategies are scarce and the few advancements made, as is the case of poly(ADP-ribose) polymerase (PARP) inhibitors, are only effective in 5% to 7% of patients. Investigators at the Third People’s Hospital of Chengdu and collaborators described the synergistic effect obtained by the combined administration of LB-23, a PARP1 degrader, and JQ1, a BRD4 inhibitor, in homologous recombination (HR)-proficient pancreatic cancer models.
Toll-like receptors (TLRs) are crucial to trigger anticancer immune responses. Despite the promise of TLR agonists as potential anticancer agents, few have reached the clinics due to concerns related to cytokine release syndrome and limited efficacy.
Small-cell lung cancer accounts for about 10%-15% of all lung cancers, yet its molecular pathogenesis remains largely unexplored due to its rapid progression and a scarcity of surgical specimens.
Simcere Zaiming Pharmaceutical Co. Ltd. has divulged E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
Shenogen Pharma Group Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety coupled to an estrogen receptor α (ER-α; ESR1)-targeting moiety through a linker reported to be useful for the treatment of cancer, infections, immunological disorders, diabetes, inflammatory and cardiovascular disorders.
RSS
